Pfizer Inc. promoted the positive findings of a small Neurontin study.
(MARK LENNIHAN/ASSOCIATED PRESS/FILE)
E-mails suggest Pfizer tried to suppress study on drug
Suits say company misled on Neurontin
Pfizer Inc. promoted the positive findings of a small Neurontin study.
(MARK LENNIHAN/ASSOCIATED PRESS/FILE)
Top drug company marketing executives suppressed a large European study suggesting their blockbuster medication Neurontin was ineffective for chronic nerve pain, and they privately strategized about how to silence a British researcher who wanted to go public with the data, according to newly filed documents and e-mails that are part of a Boston court case. (Full article: 1430 words)
This article is available in our archives:
Globe Subscribers
FREE for subscribers
Subscribers to the Boston Globe get unlimited access to our archives.
Not a subscriber?
Non-Subscribers
Purchase an electronic copy of the full article. Learn More
- $4.95 1 article
- $9.95 4 articles
- $25.95 Monthly
